Instrument Inactif

Autres langues GlaxoSmithKline plc London S.E.

Actions

Produits pharmaceutiques

Cours en clôture London S.E. Autres places de cotation
- ^GBX	-

17:00	Goldman Sachs prudent sur GSK
15:45	GSK : DZ Bank est neutre sur le titre	ZD

Autres langues

28/07	GSK plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
28/07	Gsk plc Declares Second Interim Dividend for the Second Quarter of 2026, Payable on 8 October 2026
28/07	GSK PLC : Another beat; we appreciate the new CEO's aggressive intent
28/07	Behauptet - Berichtssaison gibt den Takt vor
28/07	Earnings tonic boosts FTSE 100 as oil falls back
28/07	GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint
28/07	UK Shares Jump Amid Earnings Influx, US-Iran Talks; Unilever Updates Guidance
28/07	European Stocks Close Higher in Tuesday Trading; Consumer Goods Rally While Tech, Energy Stocks Fall
28/07	European Equities Traded in US as ADRs Ease in Tuesday Trading
28/07	GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline -- Update
28/07	JPMorgan belässt GSK auf 'Underweight' - Ziel 1700 Pence
28/07	GSK to Build New Global Research Center in Cambridge
28/07	GSK Launches Three-year Cost Savings Plan Amid Higher Second-quarter Sales, Lower Profits
28/07	GSK plc Announces Plans to Establish a Major New Global R&D Centre in Cambridge, UK
28/07	Pharmakonzern GSK legt weiter zu - Sparprogramm für mehr Geld für Forschung
28/07	GSK rüstet sich mit Milliarden-Sparprogramm für Patentabläufe
28/07	GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
28/07	Gsk plc Licensor Hansoh Pharmaceutical Group Announces Positive Results from Second Phase Iii Trial for Ris-Rez in China
28/07	GSK Q2 Core Earnings, Sales Rise; Reaffirms 2026 Guidance
28/07	Kaum verändert - Berichtssaison gibt den Takt vor
28/07	Earnings Flash (GSK) GSK Posts Q2 Revenue of 8.41B Pounds ($11.17B), vs. FactSet Est of 8.28B Pounds
28/07	GSK to Open New R&D Center in UK
28/07	GSK targets GBP1.9 billion in cost savings as profit beats forecast
28/07	Earnings Flash (GSK) GSK Posts Q2 Core EPS 50.5 Pence, vs. FactSet Est of $46.47 Pence
28/07	GSK Reports Lower H1 Attributable Profit; Turnover Rises